Related Experiment Video

Updated: Jul 14, 2026

Electrocardiogram Recordings in Anesthetized Mice using Lead II
04:16

Electrocardiogram Recordings in Anesthetized Mice using Lead II

Published on: June 20, 2020

Effect of Carvedilol on QT Duration in Paediatric Patients with Congestive Heart Failure

Thomas S Mir1, Stephanie Läer, Michele Eiselt

  • 1Klinik und Poliklinik für Kinderkardiologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.

Clinical Drug Investigation
|May 23, 2007
PubMed

Insights

Carvedilol therapy in children with heart failure improved ejection fraction and reduced heart rate and QT duration. This cardiovascular drug did not significantly alter QT dispersion, suggesting potential prognostic benefits.

Area of Science:

  • Pediatric Cardiology
  • Cardiovascular Pharmacology
  • Clinical Electrophysiology

Background:

  • Congestive heart failure (CHF) in children presents significant management challenges.
  • Electrocardiographic (ECG) parameters are crucial for assessing cardiac function and risk in pediatric CHF.
  • Carvedilol, a beta-blocker with alpha-blocking activity, is increasingly used in adult heart failure.

Purpose of the Study:

  • To evaluate the impact of carvedilol on key electrocardiographic (ECG) parameters in pediatric patients diagnosed with congestive heart failure.
  • To assess changes in heart rate, QT duration, and QT dispersion following carvedilol treatment in children with CHF.

Main Methods:

  • A cohort of 18 pediatric patients (2 months to 17 years) with CHF received carvedilol alongside standard treatments (digoxin, ACE inhibitors, diuretics).
  • Twelve-lead ECGs and echocardiography were performed at baseline and at multiple follow-up points (1, 2, 4, and 6 months).
  • ECG analysis focused on heart rate, QT duration (Bazett's and Fridericia's formulas), and QT dispersion; echocardiography assessed ejection fraction.

Main Results:

  • Carvedilol treatment led to a significant increase in mean ejection fraction (37% to 55%) and a 14% decrease in mean heart rate after 6 months.
  • Mean QT duration, measured by both Bazett's (QT(B)) and Fridericia's (QT(F)) formulas, was significantly reduced post-therapy.
  • No significant change was observed in mean QT dispersion, indicating preserved electrical stability.

Conclusions:

  • Carvedilol effectively reduces QT duration in pediatric heart failure patients, potentially by stabilizing the cardiac action potential.
  • The observed reduction in QT duration, alongside improved ejection fraction and heart rate, may contribute to a better clinical prognosis for these young patients.
  • Carvedilol does not appear to increase QT dispersion, a critical safety endpoint in cardiovascular pharmacotherapy.
Abstract

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...